## MAZIE SLATER KATZ & FREEMAN, LLC

103 Eisenhower Parkway, Suite 207, Roseland, NJ 07068 Phone: (973) 228-9898 - Fax: (973) 228-0303 www.mazieslater.com

David A. Mazie\*
Adam M. Slatter\*°
Eric D. Katz\*°
David M. Freeman
Beth G. Baldinger
Matthew R. Mendelsohn\*°
David M. Estes
Adam M. Epstein°

\*Certified by the Supreme Court of New Jersey as a Civil Trial Attorney Karen G. Kelsen° Cory J. Rothbort\*° Michael R. Griffith° Christopher J. Geddis Samuel G. Wildman Julia S. Slater° Trevor D. Dickson

°Member of N.J. & N.Y. Bars

June 17, 2024

Via ECF
Honorable Thomas I. Vanaskie, Special Master
Stevens & Lee, P.C.
1500 Market Street, East Tower, 18th Floor
Philadelphia, Pennsylvania 19103

Re: *In re Valsartan, Losartan, and Irbesartan Products Liability Litigation*, No. 1:19-md-02875-RBK (D.N.J.)

Dear Judge Vanaskie:

Please accept this letter on behalf of the Plaintiffs addressing the issues to be discussed during the June 21, 2024, status conference regarding Losartan and Irbesartan.

1. Discovery Deadlines for Losartan and Irbesartan Discovery From Manufacturers.

The Plaintiffs and the API and finished dose manufacturer Defendants negotiated search terms, custodian lists, and other issues as to the scope of custodial and non-custodial document production related to losartan and irbesartan in July and

Hon. Thomas I. Vanaskie, Special Master

June 17, 2024

Page 2

August of 2023, and Plaintiffs served their 30(b)(6) deposition notices on May 22,

2023. The manufacturer defendants began rolling productions of losartan and

irbesartan documents in the fall of 2023. The productions are not complete.

Plaintiffs request the following deadlines with regard to the API and finished

dose manufacturer defendants:

June 30, 2024: Defendants to (1) complete any outstanding document

productions, and (2) provide the identity, topics to be covered, and available

dates, for their 30(b)(6) witnesses.

September 30, 2024: Deadline to complete depositions of Defendants'

30(b)(6) and fact witnesses.

2. Losartan and Irbesartan Structured Data from Retailer Defendants.

Consistent with the Court's earlier valsartan orders, counsel for Plaintiffs

and Retail Pharmacy Defendants met and conferred to identify the losartan and

irbesartan structured data that would be provided to Plaintiffs and what events

would trigger a requirement of Retailer Pharmacy Defendants to produce the

Protected Health Information ("PHI") associated with the data to satisfy such

orders. The parties are working on a PHI order which we will submit to the Your

Honor once finalized.

Respectfully,

Adam M. Slater, Plaintiffs' Liaison Counsel

Cc: Counsel of record (via ECF)